bioRxivImmunologyPreprint
Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates
K. S. Corbett, M. C. Nason, B. Flach, M. Gagne, S. O'Connell, T. S. Johnston, S. N. Shah, V. V. Edara, K. Floyd, L. Lai, C. McDanal, J. R. Francica, B. Flynn, K. Wu, A. Choi, M. Koch, O. M. Abiona, A. P. Werner, G. S. Alvarado, S. F. Andrew, M. M. Donaldson, J. Fintzi, D. R. Flebbe, E. Lamb, A. T. Noe, , Leung
Abstract
Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. The nonhuman primate (NHP) model of SARS-CoV-2 infection replicates key features of human infection and may be used to define immune correlates of protection following vaccination. Here, NHP received either no vaccine or doses ranging from 0.3 - 100 g of mRNA-1273, a mRNA vaccine encoding the prefusion-stabilized SARS-CoV-2 spike (S-2P) protein encapsulated in a lipid nanoparticle. mRNA-1273 vaccination elicited robust circulating and mucosal antibody responses in a dose-dependent manner. Viral replication was significantly reduced in bronchoalveolar lavages and nasal swabs following SARS-CoV-2 challenge in vaccinated animals and was most strongly correlated with levels of anti-S antibody binding and neutralizing activity. Consistent with antibodies being a correlate of protection, passive transfer of vaccine-induced IgG to naive hamsters was sufficient to mediate protection. Taken together, these data show that mRNA-1273 vaccine-induced humoral immune responses are a mechanistic correlate of protection against SARS-CoV-2 infection in NHP. One-Sentence SummarymRNA-1273 vaccine-induced antibody responses are a mechanistic correlate of protection against SARS-CoV-2 infection in NHP.
- organism: non-human primate
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates
K. S. Corbett, A. Werner, … M. Suthar·bioRxiv·May 21, 2021
- Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates
K. S. Corbett, M. Gagne, … A Pekosz·bioRxiv·Aug 11, 2021
- mRNA-1273 vaccination protects against SARS-CoV-2 elicited lung inflammation in non-human primates
A. T. Waickman, K. Victor, … R. Seder·bioRxiv·Dec 24, 2021
- Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway
M. Gagne, K. S. Corbett, … B. S. Graham·bioRxiv·Oct 23, 2021
- Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
J. R. Francica, B. J. Flynn, … McDermott·bioRxiv·Mar 2, 2021
- Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates
N. van Doremalen, R. Fischer, … V. Munster·bioRxiv·Jul 7, 2021